Agnieszka Czechowicz, MD, PhD, Stanford University, Stanford, CA, outlines the obstacles to in vivo gene editing for diseases of the hematopoietic system, which mainly include concerns about the toxicity of this procedure. Currently, patients are treated with ex vivo gene editing and allogeneic cell therapies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
